TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

It also accuses the federal government of failing to "provide sufficient data to support the safety and efficacy of COVID-19 boosters." It concludes by stating that the surgeon general of Florida, Dr.

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...